EGFR and glioblastoma: Although it is known that c-Met crosstalk with EGFR, particularly EGFRvIII, drives glioblastoma pathogenesis and treatment resistance, clinical trials have yet to investigate the combination of EGFR inhibitors with c-Met inhibitors.